Next Article in Journal
Vaccine Coverage and Effectiveness in a School-Based Varicella Outbreak in Jinan Prefecture, Shandong Province
Next Article in Special Issue
Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine
Previous Article in Journal
COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects
Previous Article in Special Issue
Relative Vaccine Effectiveness of the Third Dose of CoronaVac or BNT162b2 Following a Two-Dose CoronaVac Regimen: A Prospective Observational Cohort Study from an Adult Vaccine Center in Turkey
 
 
Article

Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience

Dipartimento Materno Infantile e di Scienze Urologiche, Sapienza Università di Roma, UOC di Pediatria e Neonatologia-Polo Pontino, 04100 Latina, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Antonella Caputo
Vaccines 2022, 10(8), 1224; https://doi.org/10.3390/vaccines10081224
Received: 21 June 2022 / Revised: 27 July 2022 / Accepted: 28 July 2022 / Published: 30 July 2022
Objective: Our aim was to evaluate the safety of COVID-19 vaccine in children resident in the Latina Local Health Authority. Methods: We conducted a telephone survey among children aged 5–11 years receiving BNT162b2 mRNA COVID-19 vaccine between December 15 and 21. The main outcomes included the presence of allergic reactions or anaphylaxis, adverse events after 24–48 h, 7 and 20 days of taking the first and second doses of medications, and documented SARS-CoV-2 infection after vaccination. The information obtained was automatically linked to a spreadsheet and analyzed. Results: 569 children were enrolled. The mean age was 114 ± 4.24 months; there were 251 males in the study. The vaccine showed a favorable safety profile; no anaphylaxis or serious adverse events were reported. The most common symptoms both after the first and second dose were injection site reactions, asthenia, and headache. Injection site reactions were more frequent after the first dose (p = 0.01), while systemic symptoms were more frequent after the second dose (p = 0.022). These symptoms were more frequent in patients with comorbidities (p = 0.0159). Conclusion: Our findings confirm the safety of COVID-19 vaccine in children younger 11 years and could be useful to promote its diffusion in pediatric ages in order to achieve “herd immunity” and prevent the virus’s circulation. View Full-Text
Keywords: COVID-19; vaccine; children; adverse events COVID-19; vaccine; children; adverse events
Show Figures

Figure 1

MDPI and ACS Style

Bloise, S.; Marcellino, A.; Frasacco, B.; Gizzone, P.; Proietti Ciolli, C.; Martucci, V.; Sanseviero, M.; Del Giudice, E.; Ventriglia, F.; Lubrano, R. Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience. Vaccines 2022, 10, 1224. https://doi.org/10.3390/vaccines10081224

AMA Style

Bloise S, Marcellino A, Frasacco B, Gizzone P, Proietti Ciolli C, Martucci V, Sanseviero M, Del Giudice E, Ventriglia F, Lubrano R. Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience. Vaccines. 2022; 10(8):1224. https://doi.org/10.3390/vaccines10081224

Chicago/Turabian Style

Bloise, Silvia, Alessia Marcellino, Beatrice Frasacco, Pietro Gizzone, Claudia Proietti Ciolli, Vanessa Martucci, Mariateresa Sanseviero, Emanuela Del Giudice, Flavia Ventriglia, and Riccardo Lubrano. 2022. "Cross-Sectional Survey on BNT162b2 mRNA COVID-19 Vaccine Serious Adverse Events in Children 5 to 11 Years of Age: A Monocentric Experience" Vaccines 10, no. 8: 1224. https://doi.org/10.3390/vaccines10081224

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop